Rotterdam-based Spatium Medical, a medtech startup stemming from Erasmus MC, has raised €5 million in a new funding round. The funds will support the development of its innovative insufflation technology aimed at improving laparoscopic surgeries. The company aims to use the funds to finalize its smart insufflation device, which promises enhanced patient recovery and surgical safety.
Earlier reports highlighted Spatium Medical’s efforts in gathering support from multiple investors, with a notable round in December 2023 where they secured backing from Human Plus. The recent financial round saw contributions from new investors like InnovationQuarter and Demcon Investment Fund, along with continued support from existing backers Van Herk Ventures and Swanbridge Capital. Previous news also indicated the crucial role of the Netherlands Enterprise Agency (RVO) in funding these medical innovations.
Strategic Investments
The latest funding round for Spatium Medical attracted new investors, including InnovationQuarter and Demcon Investment Fund, while existing investors Van Herk Ventures and Swanbridge Capital also participated. These investments underscore the confidence in Spatium Medical’s potential to revolutionize laparoscopic surgeries with their advanced insufflation technology.
Investment Manager at InnovationQuarter, Nina Satih, emphasized the importance of this technology, stating,
“We are excited to see Spatium Medical’s vision come to life as they develop a technology that could drastically improve patient recovery times and surgical safety. This is exactly the type of innovation InnovationQuarter strives to support.”
The Netherlands Enterprise Agency (RVO) also supports this initiative through its Innovation Credit, reiterating its commitment to fostering groundbreaking healthcare innovations.
Innovative Technology
Spatium Medical’s smart insufflation technology aims to address the limitations of current laparoscopic procedures, which often use pressurized CO2 gas. This new device offers personalized insufflation pressure by measuring abdominal wall compliance, ensuring minimal pressure is used for optimal surgical conditions. The technology’s turbine mechanism provides greater stability, and its synchrony with mechanical ventilation reduces necessary pressures, thereby minimizing pulmonary complications.
CEO Willem Mees van der Bijl highlighted the collaborative effort behind the innovation, stating,
“Spatium’s innovative insufflation technology was born from a multi-disciplinary team of surgeons, researchers, and engineers.”
This collaboration aims to significantly improve patient outcomes in laparoscopic surgeries, making the procedures safer and more accessible.
The capital raised will enable Spatium Medical to finalize the development of the smart insufflation device and conduct clinical studies, moving towards a certified product by 2026. CEO Willem Mees van der Bijl remarked,
“The collaboration between the new and existing investors, the Netherlands Enterprise Agency (RVO) team and the Spatium Medical team has been invaluable. Not only in closing this important financial round, but also in sharing knowledge and expertise.”
This collaboration is crucial for the company’s goal of setting a new standard of care in minimally invasive surgeries worldwide.
Spatium Medical’s innovative approach in improving laparoscopic surgery outcomes holds considerable promise for the future of medical technology. By addressing key unmet needs in current practices and leveraging advanced technology, the company aims to make a lasting impact on patient care. The strategic investments and strong support from various stakeholders highlight the confidence in Spatium Medical’s vision. As the company moves towards product certification and launch, its progress will be closely watched by the medical community and investors alike.
